reMYND's Parkinson's disease drug discovery program reaches breakthrough

26-03-2007
Press release

reMYND nv announced today that it has reached a breakthrough in its drug discovery program aimed at identifying disease-modifying drugs for the treatment of Parkinson's disease. A large family of analogous compounds (coded ReS9-S) were found to possess cytoprotective properties in cellular model systems. Efficacy studies with one ReS9-S lead in a well known animal model of Parkinson's disease corroborated these highly promising results.

ReS9-S is the first in a number of chemical series developed by reMYND to attenuate the cytotoxic effects of α-synuclein aggregation in dopaminergic neurons. Degeneration and death of dopaminergic neurons of the substantia nigra is the primary cause of Parkinson's disease.

reMYND's ReS9-S represents a family of Lipinski-compliant New Chemical Entities (NCE's) which exerts cytoprotective effects in neuronal cell cultures at the low nanomolar range. reMYND demonstrated that the ReS9-S lead molecule is sufficiently brain permeable for therapeutic intervention. First in vivo data point to a complete arrest of substantia nigra degeneration in a mouse model of Parkinson s disease.

Read the complete Press Release (pdf)